GOSS

AI Memo

Gossamer Bio

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Conditional second financing closing • 2026-12-31

Base target: $10 / p=40% prob

Biggest risk

The Phase 3 primary endpoint missed its prespecified significance threshold; FDA filing acceptance would not imply approval. Failure or delay could leave a single-candidate company facing further financing needs and dilution. [#SEC-8K-2026-02-23] SEC trial-results filing

Invalidation

Break below $3 or thesis failure.

What would change my mind?

NDA acceptance could unlock conditional financing and advance seralutinib toward a possible 2027 decision. Gossamer's reacquired worldwide rights increase its potential economics if approval is ultimately achieved. [#SEC-8K-2026-09-23] SEC filing [#SEC-8K-2026-07-27] SEC rights and regulatory filing

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

$10

p=40%

Bull target

$18

p=30%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FDA filing decision on seralutinib NDA
Potential FDA approval decision
NDA acceptance could unlock conditional financing and advance seralutinib toward a possible 2027 decision.

BearKey bullets

Conditional financing depends on FDA filing acceptance in 2026 and other conditions; issuance poses substantial dilution risk.
[#SEC-8K-2026-08-21] SEC filing
PROSERA missed its prespecified primary-endpoint significance threshold; FDA may reject the filing or find the efficacy package inadequate.

WatchKey bullets

Conditional second financing closing

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $10 (p=40%)

Target spread vs base: +89% / -66%

Scenario probabilities

Bull Target: $18 (p=30%)Base Target: $10 (p=40%)Bear Target: $3 (p=30%)

Commentary

The confirmed September NDA submission remains a positive but binary regulatory development. The packet's October 16 close is $8.77; it does not establish a reliable post-submission price reaction. No post-submission analyst revisions, verified options or short-interest readings, employee score, or sufficient social coverage were supplied. Zero-valued sentiment fields indicate unavailable data, not neutral readings. The positive deterministic prior supports monitoring, while low coverage and the unresolved FDA decision limit conviction.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

FDA filing decision on seralutinib NDA
Potential FDA approval decision

Scenarios

Bull Target (Scenario probability)

$18 / p=30% prob

Base Target (Scenario probability)

$10 / p=40% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Conditional second financing closing
Approximately $125 million of proposed second-closing proceeds depend on FDA acceptance of the NDA for filing in 2026 and other closing conditions. Funding could extend runway, while the securities would substantially dilute existing holders; NDA submission alone does not trigger closing. [#SEC-8K-2026-08-21] SEC filing
Prob 60.00% • Move 10.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

FDA filing decision on seralutinib NDA
2026-12-31
Gossamer submitted its pulmonary arterial hypertension NDA in September and anticipates an FDA filing decision later in 2026. Acceptance would begin substantive review, not settle the efficacy questions. [#SEC-8K-2026-09-23] SEC filing
Prob 65% • Move 25% • Priced-in 40%

Long-term Catalysts

Months to a year

Potential FDA approval decision
2027-09-30
If the NDA is accepted, Gossamer has indicated a possible decision in the third quarter of 2027. PROSERA's primary endpoint did not meet its prespecified statistical threshold, making approval highly uncertain despite supportive analyses. [#SEC-8K-2026-07-27] SEC regulatory update [#SEC-8K-2026-02-23] SEC trial-results filing
Prob 35% • Move 100% • Priced-in 20%

Risks

Conditional financing depends on FDA filing acceptance in 2026 and other conditions; issuance poses substantial dilution risk. [#SEC-8K-2026-08-21] SEC filing
PROSERA missed its prespecified primary-endpoint significance threshold; FDA may reject the filing or find the efficacy package inadequate. [#SEC-8K-2026-02-23] SEC filing
The company is heavily dependent on seralutinib and may need additional capital if regulatory progress is delayed. [#SEC-8K-2026-09-23] SEC filing

Peers

Symbol	Summary
LQDA	PAH indication reference through approved inhaled YUTREPIA; commercial-stage economics are not comparable to Gossamer's single-candidate approval risk. Liquidia company release
TECX	Clinical-stage pulmonary-hypertension reference with a Phase 2 PH-ILD program, but its mechanism and trial stage differ from Gossamer's PAH regulatory case; not a direct valuation comparable. Tectonic company update
TENX	Late-stage pulmonary-hypertension trial-risk reference, but its PH-HFpEF population differs from Gossamer's PAH indication. Tenax company update

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

LQDA

PAH indication reference through approved inhaled YUTREPIA; commercial-stage economics are not comparable to Gossamer's single-candidate approval risk. Liquidia company release

TECX

Clinical-stage pulmonary-hypertension reference with a Phase 2 PH-ILD program, but its mechanism and trial stage differ from Gossamer's PAH regulatory case; not a direct valuation comparable. Tectonic company update

TENX

Late-stage pulmonary-hypertension trial-risk reference, but its PH-HFpEF population differs from Gossamer's PAH indication. Tenax company update